KING OF PRUSSIA, Penn., Oct. 24, 2024 /PRNewswire/ -- Universal Health Services, Inc. (NYSE: UHS) announced today that its reported net income attributable to UHS was $258.7 million, or $3.80 per diluted share, during the third quarter of 2024, as compared to $167.0 million, or $2.40 per diluted share, during the third quarter of 2023. Net revenues increased by 11.2% to $3.963 billion during the third quarter of 2024, as compared to $3.563 billion during the third quarter of 2023.
As reflected on the Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule"), our adjusted net income attributable to UHS during the third quarter of 2024 was $252.5 million, or $3.71 per diluted share, as compared to $177.5 million, or $2.55 per diluted share, during the third quarter of 2023.
As reflected on the Supplemental Schedule, included in our reported results during the third quarter of 2024 were: (i) an unrealized after-tax gain of $2.3 million, or $.03 per diluted share ($3.0 million pre-tax), resulting from an increase in the market value of certain equity securities (included in "Other (income) expense, net"), and; (ii) a favorable net after-tax impact of $3.9 million, or $.06 per diluted share, resulting from the net tax benefit recorded pursuant to "ASU 2016-09", Compensation – Stock Compensation: Improvements to Employee Share-Based Payment Accounting, net of the impact of executive compensation limitations pursuant to IRC section 162(m).
As reflected on the Supplemental Schedule, included in our reported results during the third quarter of 2023, was an after-tax loss of $10.5 million, or $.15 per diluted share ($13.8 million pre-tax), resulting from a decrease in the market value of certain equity securities.
As calculated on the attached Supplemental Schedule, our earnings before interest, taxes, depreciation & amortization ("EBITDA net of NCI", NCI is net income attributable to noncontrolling interests), was $528.6 million, or 13.3% of net revenues, during the third quarter of 2024, as compared to $410.1 million, or 11.5% of net revenues, during the third quarter of 2023. Our adjusted earnings before interest, taxes, depreciation & amortization ("Adjusted EBITDA net of NCI"), which excludes the impact of other (income) expense, net, was $526.5 million, or 13.3% of net revenues, during the third quarter of 2024, as compared to $421.5 million, or 11.8% of net revenues, during the third quarter of 2023.
Consolidated Results of Operations, As Reported and As Adjusted – Nine-month periods ended September 30, 2024 and 2023
Reported net income attributable to UHS was $809.7 million, or $11.88 per diluted share, during the first nine months of 2024, as compared to $501.4 million, or $7.09 per diluted share, during the first nine months 2023. Net revenues increased by 10.7% to $11.714 billion during the first nine months of 2024, as compared to $10.578 billion during the comparable period of 2023.
As reflected on the Supplemental Schedule, our adjusted net income attributable to UHS during the first nine months of 2024 was $798.2 million, or $11.71 per diluted share, as compared to $524.5 million, or $7.42 per diluted share, during the comparable period of 2023.
As reflected on the Supplemental Schedule, included in our reported results during the first nine months of 2024 were: (i) an unrealized after-tax loss of $4.0 million, or $.06 per diluted share ($5.3 million pre-tax), resulting from a decrease in the market value of certain equity securities (included in "Other (income) expense, net"), and; (ii) a favorable net after-tax impact of $15.5 million, or $.23 per diluted share, resulting from the above-mentioned net tax benefit recorded in connection with ASU 2016-09, net of the impact of executive compensation limitations pursuant to IRC section 162(m).
As reflected on the Supplemental Schedule, our reported results during the first nine months of 2023, included an unrealized after-tax loss of $23.0 million, or $.33 per diluted share, ($30.1 million pre-tax) resulting from a decrease in the market value of certain equity securities.
As calculated on the attached Supplemental Schedule, our EBITDA net of NCI, was $1.628 billion, or 13.9% of net revenues, during the first nine months of 2024, as compared to $1.237 billion, or 11.7% of net revenues, during the first nine months of 2023. Our Adjusted EBITDA net of NCI, which excludes the impact of other (income) expense, net, was $1.631 billion, or 13.9% of net revenues, during the first nine months of 2024, as compared to $1.268 billion, or 12.0% of net revenues, during the comparable period of 2023.
Acute Care Services – Three and nine-month periods ended September 30, 2024 and 2023
During the third quarter of 2024, at our acute care hospitals owned during both periods ("same facility basis"), adjusted admissions (adjusted for outpatient activity) increased by 1.5% while adjusted patient days increased by 2.0%, as compared to the third quarter of 2023. At these facilities, during the third quarter of 2024, net revenue per adjusted admission increased by 7.0% while net revenue per adjusted patient day increased by 6.5%, as compared to the third quarter of 2023. Net revenues generated from our acute care services, on a same facility basis, increased by 9.2% during the third quarter of 2024, as compared to the third quarter of 2023.
During the nine-month period ended September 30, 2024, at our acute care hospitals on a same facility basis, adjusted admissions increased by 3.1% while adjusted patient days increased by 2.3%, as compared to the first nine months of 2023. At these facilities, during the first nine months of 2024, net revenue per adjusted admission increased by 5.0% while net revenue per adjusted patient day increased by 5.8%, as compared to the first nine months of 2023. Net revenues generated from our acute care services, on a same facility basis, increased by 8.5% during the first nine months of 2024, as compared to the comparable period of 2023.
Behavioral Health Care Services – Three and nine-month periods ended September 30, 2024 and 2023
During the third quarter of 2024, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 2.2% while adjusted patient days increased by 1.8%, as compared to the third quarter of 2023. At these facilities, during the third quarter of 2024, net revenue per adjusted admission increased by 8.0% and net revenue per adjusted patient day increased by 8.5%, as compared to the third quarter of 2023. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 10.5% during the third quarter of 2024, as compared to the third quarter of 2023.
During the nine-month period ended September 30, 2024, at our behavioral health care facilities on a same facility basis, adjusted admissions increased by 0.3% while adjusted patient days increased by 1.7%, as compared to the first nine months of 2023. At these facilities, during the first nine months of 2024, net revenue per adjusted admission increased by 10.1% and net revenue per adjusted patient day increased by 8.7%, as compared to the first nine months of 2023. Net revenues generated from our behavioral health care services, on a same facility basis, increased by 10.6% during the first nine months of 2024, as compared to the comparable period of 2023.
Net Cash Provided by Operating Activities and Liquidity
Net Cash Provided by Operating Activities:
During the nine-month period ended September 30, 2024, our net cash provided by operating activities was $1.409 billion as compared to $815 million during the first nine months of 2023. The $593 million net increase in our net cash provided by operating activities consisted of: (i) a favorable change of $353 million resulting from an increase in net income plus/minus depreciation and amortization expense, stock-based compensation expense, gains on sales of assets and businesses and costs related to extinguishment of debt; (ii) a favorable change of $205 million in accounts receivable; (iii) a favorable change of $66 million in other working capital accounts; (iv) an unfavorable change of $55 million in other assets and deferred charges, and; (v) $24 million of other combined net favorable changes.
Liquidity:
As previously disclosed on Form 8-K on October 1, 2024, in September, 2024, we completed the following financing transactions:
As of September 30, 2024, we had $1.01 billion of aggregate available borrowing capacity pursuant to our $1.3 billion revolving credit facility, net of outstanding borrowings and letters of credit.
Stock Repurchase Program:
In July, 2024, our Board of Directors authorized a $1.0 billion increase to our stock repurchase program. Pursuant to this program, shares of our Class B Common Stock may be repurchased, from time to time as conditions allow, on the open market or in negotiated private transactions.
During the third quarter of 2024, we have repurchased 658,000 shares at an aggregate cost of approximately $153.9 million (approximately $234 per share) pursuant to the program. During the first nine months of 2024, we have repurchased 1.731 million shares at an aggregate cost of approximately $348.9 million (approximately $202 per share) pursuant to the program.
As of September 30, 2024, we had an aggregate available repurchase authorization of approximately $1.074 billion.
Conference call information:
We will hold a conference call for investors and analysts at 9:00 a.m. eastern time on October 25, 2024. A live webcast of the call will be available on our website at www.uhs.com. To participate via telephone, please register in advance at this link.
Upon registration, all telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number along with a unique passcode and registrant ID that can be used to access the call. A replay of the call will be available for one full year following the live call.
General Information, Forward-Looking Statements and Risk Factors and Non-GAAP Financial Measures:
One of the nation's largest and most respected providers of hospital and healthcare services, Universal Health Services, Inc. (the "Company") has built an impressive record of achievement and performance. Growing steadily since our inception into an esteemed Fortune 500 corporation, our annual revenues during 2023 were $14.282 billion. UHS ranked #299 on the Fortune 500; and #399 on Forbes' list of America's Largest Public Companies. UHS was again recognized as one of the World's Most Admired Companies by Fortune.
Our operating philosophy is as effective today as it was upon the Company's founding in 1979, enabling us to provide compassionate care to our patients and their loved ones. Our strategy includes building or acquiring high quality hospitals in rapidly growing markets, investing in the people and equipment needed to allow each facility to thrive, and becoming the leading healthcare provider in each community we serve.
Headquartered in King of Prussia, PA, UHS has approximately 96,700 employees and, through its subsidiaries, operates 27 inpatient acute care hospitals, 334 inpatient behavioral health facilities, 49 outpatient facilities and ambulatory care access points, an insurance offering, a physician network and various related services located in 39 states, Washington, D.C., the United Kingdom and Puerto Rico. It acts as the advisor to Universal Health Realty Income Trust, a real estate investment trust (NYSE:UHT). For additional information visit www.uhs.com.
This press release contains forward-looking statements based on current management expectations. Numerous factors, including those disclosed herein, those related to healthcare industry trends and those detailed in our filings with the Securities and Exchange Commission (as set forth in Item 2-Forward Looking Statements and Risk Factors in our Form 10-Q for the quarter ended June 30, 2024 and in Item 1A-Risk Factors, and Item 7-Forward-Looking Statements and Risk Factors, in our Form 10-K for the year ended December 31, 2023), may cause the results to differ materially from those anticipated in the forward-looking statements. These statements are subject to risks and uncertainties and therefore actual results may differ materially. Readers should not place undue reliance on such forward-looking statements which reflect management's view only as of the date hereof. We undertake no obligation to revise or update any forward-looking statements, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.
Many of the factors that could affect our future results are beyond our control or ability to predict, including, but not limited to:
We believe that adjusted net income attributable to UHS, adjusted net income attributable to UHS per diluted share, EBITDA net of NCI and Adjusted EBITDA net of NCI, which are non-GAAP financial measures ("GAAP" is Generally Accepted Accounting Principles in the United States of America), are helpful to our investors as measures of our operating performance. In addition, we believe that, when applicable, comparing and discussing our financial results based on these measures, as calculated, is helpful to our investors since it neutralizes the effect of material items impacting our net income attributable to UHS, such as, changes in the market value of shares of certain equity securities, the impact of ASU 2016-09 and other potential material items that are nonrecurring or non-operational in nature including, but not limited to, impairments of goodwill, long-lived and intangible assets, reserves for various matters including settlements, legal judgments and lawsuits, costs related to extinguishment of debt, gains/losses on sales of assets and businesses, potential impacts of non-ordinary acquisitions, divestitures, joint ventures or other strategic transactions, and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. To obtain a complete understanding of our financial performance these measures should be examined in connection with net income attributable to UHS, as determined in accordance with GAAP, and as presented in the condensed consolidated financial statements and notes thereto in this report or in our other filings with the Securities and Exchange Commission including our Report on Form 10-Q for the quarter ended June 30, 2024 and our Report on Form 10-K for the year ended December 31, 2023. Since the items included or excluded from these measures are significant components in understanding and assessing financial performance under GAAP, these measures should not be considered to be alternatives to net income as a measure of our operating performance or profitability. Since these measures, as presented, are not determined in accordance with GAAP and are thus susceptible to varying calculations, they may not be comparable to other similarly titled measures of other companies. Investors are encouraged to use GAAP measures when evaluating our financial performance.
Universal Health Services, Inc. | |||||||
Consolidated Statements of Income | |||||||
(in thousands, except per share amounts) | |||||||
(unaudited) | |||||||
Three months | Nine months | ||||||
ended September 30, | ended September 30, | ||||||
2024 | 2023 | 2024 | 2023 | ||||
Net revenues | $3,963,027 | $3,562,774 | $11,714,213 | $10,578,430 | |||
Operating charges: | |||||||
Salaries, wages and benefits | 1,912,308 | 1,784,870 | 5,611,304 | 5,308,476 | |||
Other operating expenses | 1,090,197 | 941,219 | 3,165,483 | 2,758,484 | |||
Supplies expense | 390,250 | 378,667 | 1,181,886 | 1,138,950 | |||
Depreciation and amortization | 149,567 | 137,195 | 438,050 | 422,560 | |||
Lease and rental expense | 36,540 | 35,466 | 108,165 | 105,775 | |||
3,578,862 | 3,277,417 | 10,504,888 | 9,734,245 | ||||
Income from operations | 384,165 | 285,357 | 1,209,325 | 844,185 | |||
Interest expense, net | 44,660 | 53,378 | 146,385 | 153,085 | |||
Other (income) expense, net | (2,028) | 11,472 | 3,315 | 31,797 | |||
Income before income taxes | 341,533 | 220,507 | 1,059,625 | 659,303 | |||
Provision for income taxes | 75,623 | 52,499 | 233,563 | 159,618 | |||
Net income | 265,910 | 168,008 | 826,062 | 499,685 | |||
Less: Net income (loss) attributable to | |||||||
noncontrolling interests ("NCI") | 7,196 | 1,019 | 16,362 | (1,732) | |||
Net income attributable to UHS | $258,714 | $166,989 | $809,700 | $501,417 | |||
Basic earnings per share attributable to UHS (a) | $3.89 | $2.42 | $12.11 | $7.18 | |||
Diluted earnings per share attributable to UHS (a) | $3.80 | $2.40 | $11.88 | $7.09 | |||
Universal Health Services, Inc. | |||||||
Footnotes to Consolidated Statements of Income | |||||||
(in thousands, except per share amounts) | |||||||
(unaudited) | |||||||
Three months | Nine months | ||||||
(a) Earnings per share calculation: | ended September 30, | ended September 30, | |||||
2024 | 2023 | 2024 | 2023 | ||||
Basic and diluted: | |||||||
Net income attributable to UHS | $258,714 | $166,989 | $809,700 | $501,417 | |||
Less: Net income attributable to unvested restricted share grants | 0 | (52) | (50) | (242) | |||
Net income attributable to UHS - basic and diluted | $258,714 | $166,937 | $809,650 | $501,175 | |||
Weighted average number of common shares - basic | 66,537 | 68,867 | 66,873 | 69,825 | |||
Basic earnings per share attributable to UHS: | $3.89 | $2.42 | $12.11 | $7.18 | |||
Weighted average number of common shares | 66,537 | 68,867 | 66,873 | 69,825 | |||
Add: Other share equivalents | 1,571 | 757 | 1,297 | 825 | |||
Weighted average number of common shares and equiv. - diluted | 68,108 | 69,624 | 68,170 | 70,650 | |||
Diluted earnings per share attributable to UHS: | $3.80 | $2.40 | $11.88 | $7.09 | |||
Universal Health Services, Inc. | |||||||
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule") | |||||||
For the Three Months ended September 30, 2024 and 2023 | |||||||
(in thousands, except per share amounts) | |||||||
(unaudited) | |||||||
Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI") | |||||||
Three months ended | % Net | Three months ended | % Net | ||||
September 30, 2024 | revenues | September 30, 2023 | revenues | ||||
Net income attributable to UHS | $258,714 | $166,989 | |||||
Depreciation and amortization | 149,567 | 137,195 | |||||
Interest expense, net | 44,660 | 53,378 | |||||
Provision for income taxes | 75,623 | 52,499 | |||||
EBITDA net of NCI | $528,564 | 13.3 % | $410,061 | 11.5 % | |||
Other (income) expense, net | (2,028) | 11,472 | |||||
Adjusted EBITDA net of NCI | $526,536 | 13.3 % | $421,533 | 11.8 % | |||
Net revenues | $3,963,027 | $3,562,774 | |||||
Calculation of Adjusted Net Income Attributable to UHS | |||||||
Three months ended | Three months ended | ||||||
September 30, 2024 | September 30, 2023 | ||||||
Per | Per | ||||||
Amount | Diluted Share | Amount | Diluted Share | ||||
Net income attributable to UHS | $258,714 | $3.80 | $166,989 | $2.40 | |||
Plus/minus after-tax adjustments: | |||||||
Unrealized (gain) loss on equity securities | (2,275) | (0.03) | 10,528 | 0.15 | |||
Impact of ASU 2016-09, net | (3,928) | (0.06) | - | - | |||
Subtotal adjustments | (6,203) | (0.09) | 10,528 | 0.15 | |||
Adjusted net income attributable to UHS | $252,511 | $3.71 | $177,517 | $2.55 | |||
Universal Health Services, Inc. | |||||||
Schedule of Non-GAAP Supplemental Information ("Supplemental Schedule") | |||||||
For the Nine Months ended September 30, 2024 and 2023 | |||||||
(in thousands, except per share amounts) | |||||||
(unaudited) | |||||||
Calculation of Earnings/Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization ("EBITDA/Adjusted EBITDA net of NCI") | |||||||
Nine months ended | % Net | Nine months ended | % Net | ||||
September 30, 2024 | revenues | September 30, 2023 | revenues | ||||
Net income attributable to UHS | $809,700 | $501,417 | |||||
Depreciation and amortization | 438,050 | 422,560 | |||||
Interest expense, net | 146,385 | 153,085 | |||||
Provision for income taxes | 233,563 | 159,618 | |||||
EBITDA net of NCI | $1,627,698 | 13.9 % | $1,236,680 | 11.7 % | |||
Other (income) expense, net | 3,315 | 31,797 | |||||
Adjusted EBITDA net of NCI | $1,631,013 | 13.9 % | $1,268,477 | 12.0 % | |||
Net revenues | $11,714,213 | $10,578,430 | |||||
Calculation of Adjusted Net Income Attributable to UHS | |||||||
Nine months ended | Nine months ended | ||||||
September 30, 2024 | September 30, 2023 | ||||||
Per | Per | ||||||
Amount | Diluted Share | Amount | Diluted Share | ||||
Net income attributable to UHS | $809,700 | $11.88 | $501,417 | $7.09 | |||
Plus/minus after-tax adjustments: | |||||||
Unrealized loss on equity securities | 4,038 | 0.06 | 23,040 | 0.33 | |||
Impact of ASU 2016-09, net | (15,540) | (0.23) | - | - | |||
Subtotal adjustments | (11,502) | (0.17) | 23,040 | 0.33 | |||
Adjusted net income attributable to UHS | $798,198 | $11.71 | $524,457 | $7.42 | |||
Universal Health Services, Inc. | ||||||
Condensed Consolidated Balance Sheets | ||||||
(in thousands) | ||||||
(unaudited) | ||||||
September 30, | December 31, | |||||
2024 | 2023 | |||||
Assets | ||||||
Current assets: | ||||||
Cash and cash equivalents | $ | 106,077 | $ | 119,439 | ||
Accounts receivable, net | 2,214,268 | 2,238,265 | ||||
Supplies | 220,062 | 216,988 | ||||
Other current assets | 261,549 | 236,658 | ||||
Total current assets | 2,801,956 | 2,811,350 | ||||
Property and equipment | 12,448,230 | 11,777,047 | ||||
Less: accumulated depreciation | (6,005,664) | (5,652,518) | ||||
6,442,566 | 6,124,529 | |||||
Other assets: | ||||||
Goodwill | 3,965,492 | 3,932,407 | ||||
Deferred income taxes | 121,904 | 85,626 | ||||
Right of use assets-operating leases | 421,441 | 433,962 | ||||
Deferred charges | 9,705 | 6,974 | ||||
Other | 590,784 | 572,754 | ||||
Total Assets | $ | 14,353,848 | $ | 13,967,602 | ||
Liabilities and Stockholders' Equity | ||||||
Current liabilities: | ||||||
Current maturities of long-term debt | $ | 38,351 | $ | 126,686 | ||
Accounts payable and other liabilities | 1,896,234 | 1,813,015 | ||||
Operating lease liabilities | 72,801 | 71,600 | ||||
Federal and state taxes | 3,802 | 2,046 | ||||
Total current liabilities | 2,011,188 | 2,013,347 | ||||
Other noncurrent liabilities | 660,247 | 584,007 | ||||
Operating lease liabilities noncurrent | 377,644 | 382,559 | ||||
Long-term debt | 4,618,060 | 4,785,783 | ||||
Redeemable noncontrolling interest | 5,623 | 5,191 | ||||
UHS common stockholders' equity | 6,605,696 | 6,149,001 | ||||
Noncontrolling interest | 75,390 | 47,714 | ||||
Total equity | 6,681,086 | 6,196,715 | ||||
Total Liabilities and Stockholders' Equity | $ | 14,353,848 | $ | 13,967,602 | ||
Universal Health Services, Inc. | |||
Consolidated Statements of Cash Flows | |||
(in thousands) | |||
(unaudited) | |||
Nine months | |||
ended September 30, | |||
2024 | 2023 | ||
Cash Flows from Operating Activities: | |||
Net income | $826,062 | $499,685 | |
Adjustments to reconcile net income to net | |||
cash provided by operating activities: | |||
Depreciation & amortization | 438,050 | 422,560 | |
Gains on sale of assets and businesses | (5,124) | (6,250) | |
Costs related to extinguishment of debt | 3,158 | 0 | |
Stock-based compensation expense | 72,727 | 65,702 | |
Changes in assets & liabilities, net of effects from | |||
acquisitions and dispositions: | |||
Accounts receivable | 11,703 | (193,108) | |
Accrued interest | (1,762) | 60 | |
Accrued and deferred income taxes | (10,949) | (33,240) | |
Other working capital accounts | 1,329 | (65,062) | |
Medicare accelerated payments and deferred CARES Act and other grants | 0 | 1,764 | |
Other assets and deferred charges | (5,621) | 48,985 | |
Other | 25,732 | 13,717 | |
Accrued insurance expense, net of commercial premiums paid | 175,104 | 141,414 | |
Payments made in settlement of self-insurance claims | (121,745) | (80,861) | |
Net cash provided by operating activities | 1,408,664 | 815,366 | |
Cash Flows from Investing Activities: | |||
Property and equipment additions | (697,865) | (536,665) | |
Proceeds received from sales of assets and businesses | 30,219 | 23,688 | |
Acquisition of businesses and property | 0 | (3,728) | |
Outflows from foreign exchange contracts that hedge our net U.K. investment | (35,667) | (7,723) | |
Decrease in capital reserves of commercial insurance subsidiary | 197 | 0 | |
Net cash used in investing activities | (703,116) | (524,428) | |
Cash Flows from Financing Activities: | |||
Repayments of long-term debt | (2,471,515) | (54,009) | |
Additional borrowings | 2,210,248 | 165,000 | |
Financing costs | (9,992) | (308) | |
Repurchase of common shares | (420,588) | (385,339) | |
Dividends paid | (40,302) | (41,964) | |
Issuance of common stock | 10,864 | 9,841 | |
Profit distributions to noncontrolling interests | (5,791) | (5,258) | |
Sale of ownership interests to minority members | 8,959 | 408 | |
Net cash used in financing activities | (718,117) | (311,629) | |
Effect of exchange rate changes on cash, cash equivalents and restricted cash | 2,696 | 493 | |
Increase (decrease) in cash, cash equivalents and restricted cash | (9,873) | (20,198) | |
Cash, cash equivalents and restricted cash, beginning of period | 214,470 | 200,837 | |
Cash, cash equivalents and restricted cash, end of period | $204,597 | $180,639 | |
Supplemental Disclosures of Cash Flow Information: | |||
Interest paid | $144,378 | $149,247 | |
Income taxes paid, net of refunds | $236,975 | $191,189 | |
Noncash purchases of property and equipment | $87,333 | $108,412 | |
Universal Health Services, Inc. | |||||||||
Supplemental Statistical Information | |||||||||
(unaudited) | |||||||||
% Change | % Change | ||||||||
3 Months ended | 9 Months ended | ||||||||
Same Facility: | 9/30/2024 | 9/30/2024 | |||||||
Acute Care Hospitals | |||||||||
Revenues | 9.2 % | 8.5 % | |||||||
Adjusted Admissions | 1.5 % | 3.1 % | |||||||
Adjusted Patient Days | 2.0 % | 2.3 % | |||||||
Revenue Per Adjusted Admission | 7.0 % | 5.0 % | |||||||
Revenue Per Adjusted Patient Day | 6.5 % | 5.8 % | |||||||
Behavioral Health Hospitals | |||||||||
Revenues | 10.5 % | 10.6 % | |||||||
Adjusted Admissions | 2.2 % | 0.3 % | |||||||
Adjusted Patient Days | 1.8 % | 1.7 % | |||||||
Revenue Per Adjusted Admission | 8.0 % | 10.1 % | |||||||
Revenue Per Adjusted Patient Day | 8.5 % | 8.7 % | |||||||
UHS Consolidated | Third Quarter Ended | Nine Months Ended | |||||||
9/30/2024 | 9/30/2023 | 9/30/2024 | 9/30/2023 | ||||||
Revenues | $3,963,027 | $3,562,774 | $11,714,213 | $10,578,430 | |||||
EBITDA net of NCI | $528,564 | $410,061 | $1,627,698 | $1,236,680 | |||||
EBITDA Margin net of NCI | 13.3 % | 11.5 % | 13.9 % | 11.7 % | |||||
Adjusted EBITDA net of NCI | $526,536 | $421,533 | $1,631,013 | $1,268,477 | |||||
Adjusted EBITDA Margin net of NCI | 13.3 % | 11.8 % | 13.9 % | 12.0 % | |||||
Cash Flow From Operations | $332,977 | $161,665 | $1,408,664 | $815,366 | |||||
Capital Expenditures | $247,932 | $200,001 | $697,865 | $536,665 | |||||
Days Sales Outstanding | 52 | 58 | |||||||
Debt | $4,656,411 | $4,922,629 | |||||||
UHS' Shareholders Equity | $6,605,696 | $6,064,915 | |||||||
Debt / Total Capitalization | 41.3 % | 44.8 % | |||||||
Debt / EBITDA net of NCI (1) | 2.21 | 2.97 | |||||||
Debt / Adjusted EBITDA net of NCI (1) | 2.21 | 2.83 | |||||||
Debt / Cash From Operations (1) | 2.50 | 4.42 | |||||||
(1) Latest 4 quarters. | |||||||||
Universal Health Services, Inc. | ||||||||||||||||||
Acute Care Hospital Services | ||||||||||||||||||
For the Three and Nine months ended | ||||||||||||||||||
September 30, 2024 and 2023 | ||||||||||||||||||
(in thousands) | ||||||||||||||||||
(unaudited) | ||||||||||||||||||
Same Facility Basis - Acute Care Hospital Services | ||||||||||||||||||
Three months ended | Three months ended | Nine months ended | Nine months ended | |||||||||||||||
September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||||||||||
Amount | % of Net | Amount | % of Net | Amount | % of Net | Amount | % of Net | |||||||||||
Net revenues | $2,147,732 | 100.0 % | $1,965,985 | 100.0 % | $6,355,078 | 100.0 % | $5,858,015 | 100.0 % | ||||||||||
Operating charges: | ||||||||||||||||||
Salaries, wages and benefits | 893,436 | 41.6 % | 854,284 | 43.5 % | 2,609,544 | 41.1 % | 2,517,163 | 43.0 % | ||||||||||
Other operating expenses | 598,840 | 27.9 % | 543,584 | 27.6 % | 1,754,999 | 27.6 % | 1,604,084 | 27.4 % | ||||||||||
Supplies expense | 332,799 | 15.5 % | 323,580 | 16.5 % | 1,011,602 | 15.9 % | 976,712 | 16.7 % | ||||||||||
Depreciation and amortization | 93,752 | 4.4 % | 86,437 | 4.4 % | 278,062 | 4.4 % | 273,646 | 4.7 % | ||||||||||
Lease and rental expense | 24,202 | 1.1 % | 24,443 | 1.2 % | 72,308 | 1.1 % | 72,459 | 1.2 % | ||||||||||
Subtotal-operating expenses | 1,943,029 | 90.5 % | 1,832,328 | 93.2 % | 5,726,515 | 90.1 % | 5,444,064 | 92.9 % | ||||||||||
Income from operations | 204,703 | 9.5 % | 133,657 | 6.8 % | 628,563 | 9.9 % | 413,951 | 7.1 % | ||||||||||
Interest expense, net | 1,077 | 0.1 % | (778) | (0.0) % | 3,363 | 0.1 % | (1,858) | (0.0) % | ||||||||||
Other (income) expense, net | (590) | (0.0) % | (490) | 0.0 % | (1,348) | (0.0) % | 5,723 | 0.1 % | ||||||||||
Income before income taxes | $204,216 | 9.5 % | $134,925 | 6.9 % | $626,548 | 9.9 % | $410,086 | 7.0 % | ||||||||||
All Acute Care Hospital Services | ||||||||||||||||||
Three months ended | Three months ended | Nine months ended | Nine months ended | |||||||||||||||
September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||||||||||
Amount | % of Net | Amount | % of Net | Amount | % of Net | Amount | % of Net | |||||||||||
Net revenues | $2,245,517 | 100.0 % | $2,017,288 | 100.0 % | $6,604,007 | 100.0 % | $5,993,899 | 100.0 % | ||||||||||
Operating charges: | ||||||||||||||||||
Salaries, wages and benefits | 894,551 | 39.8 % | 854,587 | 42.4 % | 2,612,118 | 39.6 % | 2,534,878 | 42.3 % | ||||||||||
Other operating expenses | 699,316 | 31.1 % | 596,834 | 29.6 % | 2,009,231 | 30.4 % | 1,731,750 | 28.9 % | ||||||||||
Supplies expense | 332,772 | 14.8 % | 323,475 | 16.0 % | 1,011,460 | 15.3 % | 979,185 | 16.3 % | ||||||||||
Depreciation and amortization | 94,522 | 4.2 % | 86,535 | 4.3 % | 279,048 | 4.2 % | 274,165 | 4.6 % | ||||||||||
Lease and rental expense | 24,490 | 1.1 % | 24,440 | 1.2 % | 72,638 | 1.1 % | 72,629 | 1.2 % | ||||||||||
Subtotal-operating expenses | 2,045,651 | 91.1 % | 1,885,871 | 93.5 % | 5,984,495 | 90.6 % | 5,592,607 | 93.3 % | ||||||||||
Income from operations | 199,866 | 8.9 % | 131,417 | 6.5 % | 619,512 | 9.4 % | 401,292 | 6.7 % | ||||||||||
Interest expense, net | 1,077 | 0.0 % | (778) | (0.0) % | 3,363 | 0.1 % | (1,858) | (0.0) % | ||||||||||
Other (income) expense, net | (527) | (0.0) % | (211) | (0.0) % | (354) | (0.0) % | 6,921 | 0.1 % | ||||||||||
Income before income taxes | $199,316 | 8.9 % | $132,406 | 6.6 % | $616,503 | 9.3 % | $396,229 | 6.6 % | ||||||||||
We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Acute Care Hospital Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2023 and our Form 10-Q for the quarter ended June 30, 2024 . | ||||||||||||||||||
The All Acute Care Hospital Services table summarizes the results of operations for all our acute care operations during the periods presented. These amounts include: (i) our acute care results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months. | ||||||||||||||||||
Universal Health Services, Inc. | ||||||||||||||||||
Behavioral Health Care Services | ||||||||||||||||||
For the Three and Nine months ended | ||||||||||||||||||
September 30, 2024 and 2023 | ||||||||||||||||||
(in thousands) | ||||||||||||||||||
(unaudited) | ||||||||||||||||||
Same Facility - Behavioral Health Care Services | ||||||||||||||||||
Three months ended | Three months ended | Nine months ended | Nine months ended | |||||||||||||||
September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||||||||||
Amount | % of Net | Amount | % of Net | Amount | % of Net | Amount | % of Net | |||||||||||
Net revenues | $1,672,453 | 100.0 % | $1,514,017 | 100.0 % | $4,972,612 | 100.0 % | $4,494,791 | 100.0 % | ||||||||||
Operating charges: | ||||||||||||||||||
Salaries, wages and benefits | 916,435 | 54.8 % | 842,683 | 55.7 % | 2,679,938 | 53.9 % | 2,494,850 | 55.5 % | ||||||||||
Other operating expenses | 313,402 | 18.7 % | 294,788 | 19.5 % | 934,107 | 18.8 % | 869,771 | 19.4 % | ||||||||||
Supplies expense | 57,723 | 3.5 % | 55,112 | 3.6 % | 171,594 | 3.5 % | 161,371 | 3.6 % | ||||||||||
Depreciation and amortization | 52,075 | 3.1 % | 47,472 | 3.1 % | 149,094 | 3.0 % | 139,358 | 3.1 % | ||||||||||
Lease and rental expense | 11,806 | 0.7 % | 10,883 | 0.7 % | 34,908 | 0.7 % | 32,684 | 0.7 % | ||||||||||
Subtotal-operating expenses | 1,351,441 | 80.8 % | 1,250,938 | 82.6 % | 3,969,641 | 79.8 % | 3,698,034 | 82.3 % | ||||||||||
Income from operations | 321,012 | 19.2 % | 263,079 | 17.4 % | 1,002,971 | 20.2 % | 796,757 | 17.7 % | ||||||||||
Interest expense, net | 1,041 | 0.1 % | 1,252 | 0.1 % | 3,076 | 0.1 % | 3,455 | 0.1 % | ||||||||||
Other (income) expense, net | (794) | (0.0) % | (985) | (0.1) % | (2,341) | (0.0) % | (2,294) | (0.1) % | ||||||||||
Income before income taxes | $320,765 | 19.2 % | $262,812 | 17.4 % | $1,002,236 | 20.2 % | $795,596 | 17.7 % | ||||||||||
All Behavioral Health Care Services | ||||||||||||||||||
Three months ended | Three months ended | Nine months ended | Nine months ended | |||||||||||||||
September 30, 2024 | September 30, 2023 | September 30, 2024 | September 30, 2023 | |||||||||||||||
Amount | % of Net | Amount | % of Net | Amount | % of Net | Amount | % of Net | |||||||||||
Net revenues | $1,714,914 | 100.0 % | $1,542,695 | 100.0 % | $5,102,290 | 100.0 % | $4,575,378 | 100.0 % | ||||||||||
Operating charges: | ||||||||||||||||||
Salaries, wages and benefits | 919,301 | 53.6 % | 844,244 | 54.7 % | 2,690,118 | 52.7 % | 2,498,338 | 54.6 % | ||||||||||
Other operating expenses | 354,331 | 20.7 % | 322,208 | 20.9 % | 1,054,007 | 20.7 % | 949,958 | 20.8 % | ||||||||||
Supplies expense | 57,830 | 3.4 % | 55,272 | 3.6 % | 172,031 | 3.4 % | 161,597 | 3.5 % | ||||||||||
Depreciation and amortization | 52,452 | 3.1 % | 47,720 | 3.1 % | 150,949 | 3.0 % | 140,117 | 3.1 % | ||||||||||
Lease and rental expense | 11,956 | 0.7 % | 10,911 | 0.7 % | 35,235 | 0.7 % | 32,834 | 0.7 % | ||||||||||
Subtotal-operating expenses | 1,395,870 | 81.4 % | 1,280,355 | 83.0 % | 4,102,340 | 80.4 % | 3,782,844 | 82.7 % | ||||||||||
Income from operations | 319,044 | 18.6 % | 262,340 | 17.0 % | 999,950 | 19.6 % | 792,534 | 17.3 % | ||||||||||
Interest expense, net | 1,041 | 0.1 % | 1,252 | 0.1 % | 3,076 | 0.1 % | 3,456 | 0.1 % | ||||||||||
Other (income) expense, net | (861) | (0.1) % | (1,080) | (0.1) % | (2,408) | (0.0) % | (3,139) | (0.1) % | ||||||||||
Income before income taxes | $318,864 | 18.6 % | $262,168 | 17.0 % | $999,282 | 19.6 % | $792,217 | 17.3 % | ||||||||||
We believe that providing our results on a "Same Facility" basis (which is a non-GAAP measure), which includes the operating results for facilities and businesses operated in both the current year and prior year periods, is helpful to our investors as a measure of our operating performance. Our Same Facility results also neutralize (if applicable), the effect of material items that are nonrecurring or non-operational in nature including items such as, but not limited to, reserves for various matters, settlements, legal judgments and lawsuits, cost related to extinguishment of debt, gains/losses on sales of assets and businesses, impairments of goodwill, long-lived and intangible assets and other amounts that may be reflected in the current or prior year financial statements that relate to prior periods. Our Same Facility basis results exclude from net revenues and other operating expenses, provider tax assessments incurred in each period. However, these provider tax assessments are included in net revenues and other operating expenses as reflected in the table under All Behavioral Health Care Services. The provider tax assessments had no impact on the income before income taxes as reflected on the above tables since the amounts offset between net revenues and other operating expenses. To obtain a complete understanding of our financial performance, the Same Facility results should be examined in connection with our net income as determined in accordance with GAAP and as presented herein and the condensed consolidated financial statements and notes thereto as contained in our Form 10-K for the year ended December 31, 2023 and our Form 10-Q for the quarter ended June 30, 2024. | ||||||||||||||||||
The All Behavioral Health Care Services table summarizes the results of operations for all our behavioral health care facilities during the periods presented. These amounts include: (i) our behavioral health results on a same facility basis, as indicated above; (ii) the impact of provider tax assessments which increased net revenues and other operating expenses but had no impact on income before income taxes, and; (iii) certain other amounts including the results of facilities acquired or opened during the last twelve months. | ||||||||||||||||||
Universal Health Services, Inc. | ||||||||||||
Selected Hospital Statistics | ||||||||||||
For the Three Months ended | ||||||||||||
September 30, 2024 and 2023 | ||||||||||||
(unaudited) | ||||||||||||
AS REPORTED: | ||||||||||||
ACUTE | BEHAVIORAL HEALTH | |||||||||||
09/30/24 | 09/30/23 | % change | 09/30/24 | 09/30/23 | % change | |||||||
Hospitals owned and leased | 27 | 27 | 0.0 % | 334 | 331 | 0.9 % | ||||||
Average licensed beds | 6,657 | 6,667 | -0.1 % | 24,446 | 24,194 | 1.0 % | ||||||
Average available beds | 6,485 | 6,495 | -0.2 % | 24,346 | 24,094 | 1.0 % | ||||||
Patient days | 393,521 | 384,348 | 2.4 % | 1,630,369 | 1,600,740 | 1.9 % | ||||||
Average daily census | 4,277.4 | 4,177.7 | 2.4 % | 17,721.4 | 17,399.3 | 1.9 % | ||||||
Occupancy-licensed beds | 64.3 % | 62.7 % | 2.5 % | 72.5 % | 71.9 % | 0.8 % | ||||||
Occupancy-available beds | 66.0 % | 64.3 % | 2.5 % | 72.8 % | 72.2 % | 0.8 % | ||||||
Admissions | 81,731 | 80,074 | 2.1 % | 121,421 | 118,487 | 2.5 % | ||||||
Length of stay | 4.8 | 4.8 | 0.3 % | 13.4 | 13.5 | -0.6 % | ||||||
Inpatient revenue | $12,277,563 | $10,916,060 | 12.5 % | $2,835,301 | $2,703,478 | 4.9 % | ||||||
Outpatient revenue | 8,573,270 | 7,480,353 | 14.6 % | 268,182 | 259,060 | 3.5 % | ||||||
Total patient revenue | 20,850,833 | 18,396,413 | 13.3 % | 3,103,483 | 2,962,538 | 4.8 % | ||||||
Other revenue | 266,822 | 251,985 | 5.9 % | 84,770 | 81,149 | 4.5 % | ||||||
Gross revenue | 21,117,655 | 18,648,398 | 13.2 % | 3,188,253 | 3,043,687 | 4.7 % | ||||||
Total deductions | 18,872,138 | 16,631,110 | 13.5 % | 1,473,339 | 1,500,992 | -1.8 % | ||||||
Net revenue | $2,245,517 | $2,017,288 | 11.3 % | $1,714,914 | $1,542,695 | 11.2 % | ||||||
SAME FACILITY: | ||||||||||||
ACUTE | BEHAVIORAL HEALTH | |||||||||||
09/30/24 | 09/30/23 | % change | 09/30/24 | 09/30/23 | % change | |||||||
Hospitals owned and leased | 27 | 27 | 0.0 % | 333 | 333 | 0.0 % | ||||||
Average licensed beds | 6,657 | 6,667 | -0.1 % | 24,277 | 24,012 | 1.1 % | ||||||
Average available beds | 6,485 | 6,495 | -0.2 % | 24,177 | 23,912 | 1.1 % | ||||||
Patient days | 393,521 | 384,348 | 2.4 % | 1,618,344 | 1,586,108 | 2.0 % | ||||||
Average daily census | 4,277.4 | 4,177.7 | 2.4 % | 17,590.7 | 17,240.3 | 2.0 % | ||||||
Occupancy-licensed beds | 64.3 % | 62.7 % | 2.5 % | 72.5 % | 71.8 % | 0.9 % | ||||||
Occupancy-available beds | 66.0 % | 64.3 % | 2.5 % | 72.8 % | 72.1 % | 0.9 % | ||||||
Admissions | 81,731 | 80,074 | 2.1 % | 120,515 | 117,635 | 2.4 % | ||||||
Length of stay | 4.8 | 4.8 | 0.3 % | 13.4 | 13.5 | -0.4 % | ||||||
Universal Health Services, Inc. | ||||||||||||
Selected Hospital Statistics | ||||||||||||
For the Nine Months ended | ||||||||||||
September 30, 2024 and 2023 | ||||||||||||
(unaudited) | ||||||||||||
AS REPORTED: | ||||||||||||
ACUTE | BEHAVIORAL HEALTH | |||||||||||
09/30/24 | 09/30/23 | % change | 09/30/24 | 09/30/23 | % change | |||||||
Hospitals owned and leased | 27 | 27 | 0.0 % | 334 | 331 | 0.9 % | ||||||
Average licensed beds | 6,657 | 6,697 | -0.6 % | 24,413 | 24,203 | 0.9 % | ||||||
Average available beds | 6,485 | 6,525 | -0.6 % | 24,313 | 24,103 | 0.9 % | ||||||
Patient days | 1,199,271 | 1,172,957 | 2.2 % | 4,858,431 | 4,761,887 | 2.0 % | ||||||
Average daily census | 4,376.9 | 4,296.5 | 1.9 % | 17,731.5 | 17,442.8 | 1.7 % | ||||||
Occupancy-licensed beds | 65.7 % | 64.2 % | 2.5 % | 72.6 % | 72.1 % | 0.8 % | ||||||
Occupancy-available beds | 67.5 % | 65.8 % | 2.5 % | 72.9 % | 72.4 % | 0.8 % | ||||||
Admissions | 247,170 | 239,300 | 3.3 % | 361,149 | 358,703 | 0.7 % | ||||||
Length of stay | 4.9 | 4.9 | 0.0 % | 13.5 | 13.3 | 1.7 % | ||||||
Inpatient revenue | $37,522,395 | $33,278,396 | 12.8 % | $8,375,470 | $8,001,838 | 4.7 % | ||||||
Outpatient revenue | 25,553,451 | 22,292,249 | 14.6 % | 833,260 | 812,467 | 2.6 % | ||||||
Total patient revenue | 63,075,846 | 55,570,645 | 13.5 % | 9,208,730 | 8,814,305 | 4.5 % | ||||||
Other revenue | 747,424 | 714,877 | 4.6 % | 247,182 | 220,393 | 12.2 % | ||||||
Gross revenue | 63,823,270 | 56,285,522 | 13.4 % | 9,455,912 | 9,034,698 | 4.7 % | ||||||
Total deductions | 57,219,263 | 50,291,623 | 13.8 % | 4,353,622 | 4,459,320 | -2.4 % | ||||||
Net revenue | $6,604,007 | $5,993,899 | 10.2 % | $5,102,290 | $4,575,378 | 11.5 % | ||||||
SAME FACILITY: | ||||||||||||
ACUTE | BEHAVIORAL HEALTH | |||||||||||
09/30/24 | 09/30/23 | % change | 09/30/24 | 09/30/23 | % change | |||||||
Hospitals owned and leased | 27 | 27 | 0.0 % | 333 | 333 | 0.0 % | ||||||
Average licensed beds | 6,657 | 6,634 | 0.3 % | 24,189 | 24,060 | 0.5 % | ||||||
Average available beds | 6,485 | 6,462 | 0.4 % | 24,089 | 23,960 | 0.5 % | ||||||
Patient days | 1,199,271 | 1,166,693 | 2.8 % | 4,819,550 | 4,726,531 | 2.0 % | ||||||
Average daily census | 4,376.9 | 4,273.6 | 2.4 % | 17,589.6 | 17,313.3 | 1.6 % | ||||||
Occupancy-licensed beds | 65.7 % | 64.4 % | 2.1 % | 72.7 % | 72.0 % | 1.1 % | ||||||
Occupancy-available beds | 67.5 % | 66.1 % | 2.1 % | 73.0 % | 72.3 % | 1.1 % | ||||||
Admissions | 247,170 | 238,237 | 3.7 % | 358,114 | 356,028 | 0.6 % | ||||||
Length of stay | 4.9 | 4.9 | 0.0 % | 13.5 | 13.3 | 1.5 % | ||||||
| Last Trade: | US$196.66 |
| Daily Change: | -0.86 -0.44 |
| Daily Volume: | 447,080 |
| Market Cap: | US$11.550B |
October 29, 2024 June 07, 2024 | |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
